

Elisa Melucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9530997/publications.pdf>

Version: 2024-02-01

27
papers

986
citations

516215

16
h-index

552369

26
g-index

27
all docs

27
docs citations

27
times ranked

2138
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients. <i>Biosensors and Bioelectronics</i> , 2020, 170, 112648.	5.3	24
2	The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	2.1	11
3	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 247.	1.8	6
4	Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages. <i>Breast Cancer Research</i> , 2018, 20, 59.	2.2	38
5	Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	2.1	12
6	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	1.8	13
7	Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 124.	3.5	25
8	Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating <i>EWS-FLI1</i> fusion transcripts. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877433.	1.4	26
9	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	2.3	30
10	Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC). <i>Scientific Reports</i> , 2016, 6, 34006.	1.6	16
11	Human papillomavirus 16 E2 interacts with neuregulin receptor degradation protein 1 affecting ErbB-3 expression in vitro and in clinical samples of cervical lesions. <i>European Journal of Cancer</i> , 2016, 58, 52-61.	1.3	10
12	UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. <i>Oncotarget</i> , 2016, 7, 44113-44128.	0.8	17
13	Effect of polymorphisms and miRNAs targeting CLOCK gene on gender-related survival in metastatic colorectal cancer (mCRC) patients (pts). <i>Journal of Clinical Oncology</i> , 2015, 33, e14585-e14585.	0.8	0
14	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	0.8	11
15	Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensitivity after radioembolization with yttrium-90 resin microspheres. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 13.	3.5	16
16	Overexpression of activated phospholipase C β 1 is a risk factor for distant metastases in T1 \leq T2, N0 breast cancer patients undergoing adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2013, 132, 1022-1031.	2.3	41
17	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. <i>Clinical Cancer Research</i> , 2011, 17, 2055-2064.	3.2	92
18	Human Leukocyte Antigen E Contributes to Protect Tumor Cells from Lysis by Natural Killer Cells. <i>Neoplasia</i> , 2011, 13, 822-IN14.	2.3	73

#	ARTICLE	IF	CITATIONS
19	Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies. <i>Oncology</i> , 2010, 78, 141-149.	0.9	29
20	Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab. <i>Journal of Translational Medicine</i> , 2010, 8, 36.	1.8	16
21	The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e15852.	1.1	23
22	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 1086-1093.	3.6	182
23	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 717-725.	1.1	39
24	A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. <i>Breast Cancer Research</i> , 2008, 10, R74.	2.2	89
25	HLA-E: Strong Association with β 2-Microglobulin and Surface Expression in the Absence of HLA Class I Signal Sequence-Derived Peptides. <i>Journal of Immunology</i> , 2008, 181, 5442-5450.	0.4	37
26	Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines. <i>Clinical Cancer Research</i> , 2008, 14, 4943-4950.	3.2	63
27	Induction of ErbB-3 Expression by β 1 β 4 Integrin Contributes to Tamoxifen Resistance in ER β 1-Negative Breast Carcinomas. <i>PLoS ONE</i> , 2008, 3, e1592.	1.1	47